The Human Cost of IVF: A Doctor’s Journey Through Two Nations’ Systems
A stark comparison of infertility treatment in the US and Korea reveals a critical tension between efficiency and individualized care, leaving many patients feeling lost in the statistics.
The path to parenthood is rarely linear, and for many, it leads through the complex world of in vitro fertilization (IVF). But what that journey feels like can vary dramatically depending on where in the world it takes place. One physician, navigating IVF alongside his wife, offers a deeply personal and critical look at the contrasting approaches to infertility treatment in Korea and the United States, revealing a system where statistical success often overshadows the individual human experience.
“It is difficult to say what is right and what is wrong,” the doctor reflects, acknowledging the emotional weight of the process. “For some, it is a miraculous process, for others, it is the beginning of a long tunnel.” His own experience – five rounds of IVF, including three chemical pregnancies – underscores the emotional toll. “Hope and frustration intersect several times a day,” he recounts, “In the end, the hardest thing was the weight of the question, ‘Will it work this time?’”
Korea: Efficiency at a Human Cost
South Korea has established itself as a global leader in infertility treatment, lauded for its accessibility, speed, and cost-effectiveness. However, this efficiency comes at a price. According to the physician, the Korean system operates with a structure “in which one person’s story disappears into statistics.”
This is particularly concerning for women in their 40s, who often undergo embryo transfers on day 3 without the benefit of Preimplantation Genetic Testing for Aneuploidy (PGT-A) – a process that screens embryos for chromosomal abnormalities. Repeated attempts are often met with the well-intentioned but ultimately insufficient phrase, “I hope it goes well this time.” The doctor questioned whether this approach truly represented the standard of care in an advanced nation.
The pressures of time and limited insurance coverage contribute to a system where doctors are often forced to choose “the best within the scope possible,” rather than pursuing the optimal course of treatment. Ultimately, failure is often attributed to the patient’s body or, simply, fate.
The American Approach: A Slow, But Thorough Path
The experience in the United States was a stark contrast. As the physician’s wife passed 8 weeks and 5 days of pregnancy, she received comprehensive treatment including immunomodulation, thrombosis prevention, and hormonal support – interventions that surprised even him as a medical professional.
Unlike the Korean system, failure was not dismissed as bad luck. Instead, a thorough investigation of all possibilities was undertaken, and decision-making power was consistently returned to the couple. While slower and more expensive, the American approach offered a crucial sense of agency and the assurance that “we did everything we could.”
Beyond Technology: A Difference in Perspective
The physician’s journey led him to explore the underlying reasons for these systemic differences, even consulting with ChatGPT to analyze the disparities. He concluded that the core distinction wasn’t a matter of technology or resources, but rather, “how medicine views humans.”
The American system, he observed, prioritizes controlling every possible variable, embracing a philosophy of intensive scientific intervention. Korea, on the other hand, centers on statistics and efficiency, aiming for “good outcomes for the majority.” While not inherently negative, this approach risks excluding those who fall outside the average.
Recurrent Miscarriage: A Gap in Global Standards
A review of recent guidelines from the American Society for Reproductive Medicine (ASRM) highlights a growing recognition of the need for comprehensive evaluation in cases of recurrent pregnancy loss (RPL). ASRM recommends systematic assessment of uterine structure, blood clots, hormones, and chromosomal abnormalities.
PGT-A is also recognized as a potential tool to increase implantation and birth rates in RPL or repeated implantation failure, though it is not universally recommended. Furthermore, studies suggest potential benefits from immunity and blood clot treatments in specific cases, such as antiphospholipid antibody syndrome.
Despite these established guidelines, the physician notes that such evaluations and approaches remain limited in Korean clinical settings, constrained by time, insurance, and institutional factors. This often leaves patients feeling stigmatized with the label of having a “bad uterus.” .
The Essence of Medicine: Respect and Understanding
Ultimately, this experience profoundly shifted the physician’s perspective, both as a doctor and as a husband. He realized the importance of recognizing “the people behind statistics.”
“The essence of medicine is not success rate, but respect and understanding,” he concludes, “and it may be a process of listening to each person’s story.” While acknowledging the strengths of Korea’s medical care, he believes that a more human-centered approach is essential to truly elevate it to a world-class standard.
